Development of Promising Alzheimer's Vaccine Halted
March 4, 2002
Pharmaceutical maker Elan Corporation has permanently halted the development of its experimental Alzheimer's vaccine, AN-1792. Recently, clinical trials of the drug were suspended after four patients in France developed inflammation of the central nervous system (CNS). Researchers decided to permanently halt the vaccine's development after a dozen more users suffered adverse side effects.
The cause of the complications is still unknown. The vaccine, which appeared to work by stimulating the immune system to "recognize" and attack the build-up of amyloid plaque, a substance believed to be characteristic of the neurological disorder, was thought to be a major victory in the fight against Alzheimer's disease.
-- Article Courtesy of InjuryBoard.com
More ...
- National Vaccine Injury Compensation Program: FAQ
- LYMErix / Lyme Disease Vaccine
- Lyme Disease Vaccine Associated With Arthritis?
.